The use of somatotropin and myopia Original research study

Article Sidebar

PDF PDF (Język Polski)


Published: Dec 31, 2022
DOI: https://doi.org/10.24292/01.OT.311222.3
Keywords:
somatotropin, myopia, eye axial length

Main Article Content

Marek E. Prost
1. Department of Ophthalmology, Military Institute of Aviation Medicine, Warsaw, Poland. 2. Centre for Paediatric Ophthalmology, Warsaw, Poland
http://orcid.org/0000-0002-5620-4171

Abstract

Aim of the study: Long-term observation of changes of the eye axial length and refraction in children treated with growth hormone.


Material and methods: The studies were performed in 11 children treated with somatropin, who had eye examinations performed annually, including measurements of the eye axial length and refraction. The observation period was 5–9 years.


Results: 55% of the observed children showed an excessively increase in the axial eye length and the development or progression of pre-existing myopia.


Conclusion: The use of somatropin in children may cause excessive elongation of the eye axial length and the development or progression of pre-existing myopia.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Prost ME. The use of somatotropin and myopia. Ophthatherapy [Internet]. 2022Dec.31 [cited 2024Nov.21];9(4):226-9. Available from: https://journalsmededu.pl/index.php/ophthatherapy/article/view/2672
Issue
Vol 9 No 4 (2022)
Section
Conservative treatment
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. DiVall SA, Radovick S. Growth hormone and treatment controversy; long term safety of rGH. Curr Pediatr Rep. 2013; 1(2): 128-32.
2. Reeves GD, Doyle DA. Growth hormone treatment and pseudotumor cerebri: coincidence or close relationship? J Pediatr Endocrinol Metab. 2002; 15(suppl 2): 723-30.
3. Urban B, Gardziejczyk M, Urban M et al. Wpływ leczenia ludzkim hormonem wzrostu na oczy u pacjentów z somatropinową niewydolnością przysadki i u dziewczynek z zespołem Turnera. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2005; 11(1): 9-12.
4. Fawzy A, El-Said Badawi N, Ismail MM et al. Possible Effects of Growth Hormone Therapy on the Eye. Med J Cairo Univ. 2019; 87(5): 2963-6.
5. Solomon AS, Hagin D. The effect of the growth hormone on the axial elongation of rat eyes. Invest Ophthalmol Vis Sci. 2004; 45(13): 1242.
6. Parentin F, Perissutti P. Congenital growth hormone deficiency and eye refraction: a longitudinal study. Ophthalmologica. 2005; 219(4): 226-31.
7. Mukamal R. Growth Hormone Therapy and Children’s Eyes. American Academy of Ophthalmology. 2020; Dec. 21.
8. Prost M (ed). Rozwój gałki ocznej u dziecka. IPCZD, Warszawa 2000.
9. Czepita D, Żejmo M, Mojsa A. Prevalence of myopia and hyperopia in a population of Polish school children. Ophthalmic Physiol Opt. 2007; 27: 60-5.